Wu H, Zhao H Y
Department of Nuclear and Internal Medicine, Tongji Hospital, Wuhan.
Chin Med J (Engl). 1994 May;107(5):342-6.
Since only oral preparations of captopril are clinically available, intravenous captopril was studied in 10 patients with mild heart failure and in 20 severe. The results showed that intravenous captopril may rapidly reduce cardiac preload and afterload, increase cardiac output, inhibit renin-angiotensin-aldosterone system, and depress plasma levels of catecholamine. After captopril infusion, a rapid symptomatic improvement occurred and the infusion could be well tolerated in patients with acute or severe heart failure. In addition, reversing hyponatremia and hypokalemia or improving azotemia may benefit the patients with acute or severe heart failure.
由于临床上只有卡托普利的口服制剂，因此对10例轻度心力衰竭患者和20例重度心力衰竭患者进行了静脉注射卡托普利的研究。结果表明，静脉注射卡托普利可迅速降低心脏前负荷和后负荷，增加心输出量，抑制肾素-血管紧张素-醛固酮系统，并降低血浆儿茶酚胺水平。输注卡托普利后，症状迅速改善，急性或重度心力衰竭患者对输注耐受性良好。此外，纠正低钠血症和低钾血症或改善氮质血症可能对急性或重度心力衰竭患者有益。
